Current updates in management of relapsed/refractory small cell lung cancer

被引：3
作者：
Abughanimeh, Omar [1 ]
Ernani, Vinicius [1 ]
Marr, Alissa [1 ]
Ganti, Apar Kishor [1 ,2 ]
机构：
[1] Univ Nebraska Med Ctr, Dept Internal Med, Div Hematol & Oncol, Fred & Pamela Buffett Canc Ctr, 986840 Nebraska Med Ctr, Omaha, NE 68198 USA
[2] VA Nebraska Western Iowa Hlth Care Syst, Div Hematol & Oncol, Omaha, NE 68198 USA
来源：
JOURNAL OF CANCER METASTASIS AND TREATMENT | 2020年 / 6卷
关键词：
Small cell lung cancer; relapsed small cell lung cancer; chemotherapy; immunotherapy; targeted therapy; PHASE-II TRIAL; NIVOLUMAB PLUS IPILIMUMAB; 2ND-LINE TREATMENT; OPEN-LABEL; LURBINECTEDIN PM01183; PRETREATED PATIENTS; CHECKMATE; 032; TOPOTECAN; CHEMOTHERAPY; RECURRENT;
D O I：
10.20517/2394-4722.2020.110
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Small cell lung cancer (SCLC) is an aggressive subtype of neuroendocrine tumor. It is characterized by a rapid doubling time and early development of metastatic disease. Despite being responsive to initial chemotherapy, most of the patients will have relapse of the disease within a few months. The prognosis of SCLC is dismal with a 5-year survival rate of less than 5%. For that reason, management of SCLC has been an active area of research. The utilization of immunotherapy has provided promising results in treatment of SCLC in the front-line setting. Therefore, utilization of immunotherapy and targeted therapy is being studied in the setting of relapsed/ refractory disease, and currently, different clinical trials are exploring new drugs and further options. In this review, we will explore the latest updates in management of relapsed/refractory SCLC.
引用
收藏
页数：13
相关论文
共 50 条
  • [21] Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer
    Chiang, Anne C.
    Sequist, Lecia Van Dam
    Gilbert, Jill
    Conkling, Paul
    Thompson, Dana
    Marcoux, J. Paul
    Gettinger, Scott
    Kowanetz, Marcin
    Molinero, Luciana
    O'Hear, Carol
    Fasso, Marcella
    Lam, Sivuonthanh
    Gordon, Michael S.
    [J]. CLINICAL LUNG CANCER, 2020, 21 (05) : 455 - +
  • [22] Current and Emerging Pharmacotherapies for the Treatment of Relapsed Small Cell Lung Cancer
    Nair, Binu S.
    Bhanderi, Vipul
    Jafri, Syed H.
    [J]. CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2011, 5 : 223 - 234
  • [23] Challenges and opportunities in the immunotherapy era: balancing expectations with hope in small-cell lung cancer
    Khan, Raza
    Coleman, Niamh
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [24] Relapsed small cell lung cancer: treatment options and latest developments
    Asai, Nobuhiro
    Ohkuni, Yoshihiro
    Kaneko, Norihiro
    Yamaguchi, Etsuro
    Kubo, Akihito
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2014, 6 (02) : 69 - 82
  • [25] Multidisciplinary Management of Small Cell Lung Cancer
    Goldberg, Sarah B.
    Willers, Henning
    Heist, Rebecca S.
    [J]. SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 22 (02) : 329 - +
  • [26] Anlotinib plus oral fluoropyrimidine S-1 in refractory or relapsed small-cell lung cancer (SALTER TRIAL): a multicenter, single-arm, phase II trial
    Wang, Wei
    Wu, Guixian
    Luo, Wujun
    Lin, Ling
    Zhou, Chao
    Yao, Guifei
    Chen, Meifang
    Wu, Xiaomai
    Chen, Ziran
    Ye, Junhui
    Yang, Haihua
    Lv, Dongqing
    [J]. BMC CANCER, 2024, 24 (01)
  • [27] Emerging therapies for small cell lung cancer
    Yang, Sen
    Zhang, Zhe
    Wang, Qiming
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
  • [28] Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer
    Yu, Lin
    Lai, Qinhuai
    Gou, Lantu
    Feng, Jiafu
    Yang, Jinliang
    [J]. JOURNAL OF DRUG TARGETING, 2021, 29 (01) : 1 - 11
  • [29] Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort
    Schmid, Sabine
    Mauti, Laetitia A.
    Friedlaender, Alex
    Blum, Veronika
    Rothschild, Sacha I.
    Bouchaab, Hasna
    Frosch, Patrizia
    Britschgi, Christian
    Konig, David
    Wannesson, Luciano
    Janthur, Wolf-Dieter
    Schar, Sami
    Demmer, Izadora
    Addeo, Alfredo
    Jochum, Wolfram
    Fruh, Martin
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (08) : 1605 - 1613
  • [30] Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer
    Heist, Rebecca Suk
    Fain, Jerry
    Chinnasami, Bernard
    Khan, Waseem
    Molina, Julian R.
    Sequist, Lecia V.
    Temel, Jennifer S.
    Fidias, Panos
    Brainerd, Valari
    Leopold, Lance
    Lynch, Thomas J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) : 1637 - 1643
12345